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Abstract
Antibiotic-resistant strains of bacteria may result in serious infections which are difficult
to treat. In addition, the poor antibiotic pipeline has also contributed to the crisis. Recently, the
complex of furosemide and silver (Ag-FSE) has been reported as a potential antibacterial agent.
However, its poor aqueous solubility is limiting its activity as an effective antibacterial agent. The
purpose of this study was to encapsulate Ag-FSE into chitosan nanoparticles (CSNPs) and evaluate
antibacterial efficacy. Ag-FSE CSNPs were prepared using ionic gelation technique. The particle
size, polydispersity index and zeta potential of Ag-FSE CSNPs were determined using dynamic
light scattering (DLS) technique. Encapsulation efficiency and drug release studies were also
performed and evaluated with the formulated Ag-FSE loaded CSNPs. To gain an insight into the
formulation’s effectiveness, in vitro antibacterial activity studies were also performed. Stability
studies with the Ag-FSE loaded CSNPs were executed to understand the most optimal storage
conditions for an extended storage life of the formulation to be appropriate. Based upon results
and interpretations, it could be determined that the study is viable to continue forward for further
studies.
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Chapter 1: Bacterial Infections & The Revolution of Medicine
The evolution of prokaryotic and eukaryotic cells has been at times dichotomous, and
alternatively a collaborative relationship [1]. Within the human system, microbiomes of bacteria
can be found involved with multitudes of processes, such as digestion, and nutrient absorption [2].
Alternatively, constant competition of survival for both forms of life exist, and thus “survival of
the fittest” has led to the development of disease, infections, and uncontrolled plagues. This
competitive nature of bacteria infecting and propagating along the human system brought the need
for drug discovery, and formulation of medication. With efforts in producing antibiotics, diseases
became eradicated, and infections became controlled & treatable. However, this same solution
metamorphosized into the downfall of effective antibiotics, leading to new generations of bacteria,
resistant to those once effective treatments.
SECTION 1.1. BACTERIAL INFECTIONS
The competitive nature between eukaryotic and prokaryotic organisms may lead to illness
within a host. Bacteria, although simple single-celled entities with no nucleus or any other
advanced features, prove to be burdensome when entering a system for competitive existence.
Although many existing bacteria within the human system work symbiotically, some foreign
bacterium act to dominate regions. When unchecked, the site of infection can propagate the genesis
of serious complications.
Bacteria competing and overwhelming the immune system leads to the development of
diseased states [3,4]. Easily contracted diseases could develop into plagues, shaping society and
the ideals of modern medicine [5]. Specifically, into understanding the nature of bacteria and
classifying types of bacteria found in common diseases and infections. Scientists observed that
bacteria in common infections shared a common morphology [6–9].
Treatment of bacterial infections was possible with the determination that common
infections were propagated due to a common bacterium. Common characteristics observed rooted
in the form of morphology that the bacteria had. Synthesis of compounds to treat specific bacteria
1

for specific infections would lead to a medical revolution. A revolution in which eradication of
bacterial infections caused by the discovery and production of antibiotics would be underway.
SECTION 1.2. ANTIBIOTIC EVOLUTION
Discovery and development of antibiotics became a pivotal moment, which eradicated
diseases and increased the average life expectancy from 47 to over 70 years [10]. Yet, centuries
before the discovery and use of antibiotics, individuals who contracted an infection primarily relied
on holistic remedies with plant extracts or molds [11]. Ancient Egyptian and Sudanese practices
indicated that knowledge of certain properties found in molds and other plant-based remedies
would be used to treat infected wounds and other illnesses [11–13]. This gave rise to the notion
that early forms of antibiotics had been used but with little understanding of the mechanisms of
action.
Motivation to uncover solutions to infection and disease-causing bacterium initiated with
early concepts of antibiotics during the late 19th and early 20th century. Early records of antibiotic
development and discovery was recorded by Robert Emmerich and Oscar Löw [13]. Emmerich
and Löw observed that a particular bacterium growing within the bandages of patients would
inhibit the propagation of any other types of bacteria [13]. Although it had been determined an
unfavorable solution with Emmerich and Löw’s attempt, the door for new possibilities of treatment
methods opened particularly for targeted treatment of bacterial infections.
The concept of specific and targeted treatment for bacterial infections with synthetic
compounds was presented in the early 20th century by Paul Ehrlich [14]. Ehrlich’s early concepts
of dyes, such as methylene blue, was used to tag bacterium for specific treatment of infections.
This method of staining was the basis for many early synthetic compounds in discovering the
“magic bullet”. The “magic bullet” is a concept which describes that a specific compound would
target and destroy a specific bacterium based on chemical structure compatibility with no harm to
uninfected host tissue [15,16].
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These initiatives created the stepping stone for the first true antibiotics and revolution of
pharmacological practice in treating diseases. Ehrlich’s discovery of benzoporporine and a later
derivative, Trypan red, allowed for the successful treatment of trypanosomal (malaria) infections
[15]. Later, the discovery of the compound arsphenamine (Sulvarsan) was Ehlrich’s 606th
compound was used to treat syphilis [15,16]. Through trial and error of synthesis and molecular
structuring of compounds with affinities to specific bacteria [15] were the first “antibiotics”
discovered.
In a serendipitous discovery, the first true antibiotic was uncovered by Alexander Fleming
[17]. Fleming’s observation of a mold, Penicillium notatum, in a petri dish of Staphylococcuss
bacteria transfecting itself to inhibit the bacterial propagation unveiled that through nature
treatments for bacterial infections existed [11,18]. Penicillin’s discovery sparked an advancement
in antibiotic discovery which begun with Selman Waksman’s work in discovering streptomycin to
treat tuberculosis [19]. The golden era of antibiotics followed these initial breakthrough’s with
eradication of various diseases and infections which havocked society.
SECTION 1.3. DECLINE OF THE ANTIBIOTIC GOLDEN ERA
Early into the golden era of antibiotics, it was quickly observed that bacteria were acquiring
resistance to the discovered antibiotics and to those remedies used beforehand with similar molds
or bacteria [10,12,13,20]. Because of this early detection of resistance, generations of antibiotic
derivatives were synthesized becoming the order of production for new antibiotics [13]. With
focuses shifted from discovering novel antibiotics to producing derivatives of existing antibiotics,
led to the gradual decline of the antibiotic pipeline. Other factors leading to the drying of the
pipeline included the cost of drug discovery efforts and increasingly intensified FDA standards for
clinical trials in protection of human subjects [20,21]. Along with focuses in medicine reshuffling
to advance medical technology, caused a halt with antibiotic discovery [12,21].
Due to unsuccessful attempts and belief that all accessible scaffolds for new antibiotics had
been uncovered, pharmaceutical focuses and investments for novel antibiotics seized leading to
3

the evolution of antibiotic resistant bacteria [21]. Infections that were once treatable, aggressively
resurfaced with difficulty in implementing treatment methods. Combination therapies and
increased dosages were utilized to treat infections with resistance bacteria. This improper use of
prescribed drugs or low patient compliance would lead to the emergence of multiple-drug resistant
bacteria [22–25]. This issue of bacterial resistance was forecasted to increase rates of mortality to
treatable diseases and infections [26] unless revival of the current antibiotics were to occur.
SECTION 1.4. REVIVAL OF ANTIBIOTICS WITH NANOTECHNOLOGY
The threat of emerging drug resistant bacteria to send society back into a period of preantibiotics created the urgency to develop methodologies to revive the efficacy of existing
antibiotics (Figure 1.1). Advancement of nanotechnology within the medicine, nanomedicine, had
shown promise in overcoming the issue with drug resistant bacteria [27,28]. Nanomedicine could
be utilized with a plethora of practices from wound healing promotion to infection prevention [25].
With high reproducibility, low cost effectiveness, high tunability, ease of modification, and target
specificity, nanomedicine could be a favorable route of enhancing existing antibiotic effectiveness
[23,25,27–29].

Figure 1.1: Timeline of the rise and fall of antibiotics.
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Major drawbacks with existing antibiotics include low bioavailability within human
physiological conditions, along with poor penetrability of the compound to the bacterial cell wall
[22]. These drawbacks are also essential properties for antibiotics to hold susceptibility in treating
bacterial infections and diseases, but when compromised are linked to the rise of resistant bacteria
[22]. In response, research initiatives to develop nanotechnology platforms to improve properties
of bioavailability, cell wall penetrability, as well as enhanced site specificity, prolonged
therapeutic effects, biodegradability, biocompatibility for enhanced efficacy were of focus [24].
Formulating nanoparticles to combat antibiotic resistant bacteria aimed to enhance efficacy
of existing antibiotics is one of many aspects with utilizing nanotechnology. Unique characteristics
associated with nanoparticles is the ease of optimizing intrinsic physicochemical properties of the
nanoparticles. Modification to nanoparticles for enhanced target site specificity, increased cellular
interactions, improved drug encapsulation and release properties, while also improving solubility
of poorly soluble drugs would be possible [24,25,30]. Nanoparticles used as drug delivery vehicles
could vastly improve pharmacokinetic and pharmacodynamic properties to improve
bioavailability for effective treatment methods against bacterial infections [22,27,30].
Nanoparticles with materials of either organic or inorganic nature also hold high influence
with properties such as biodegradability, biocompatibility and antibiotic activity for enhanced
efficacy [31]. Careful material selection could prove useful to provide synergistic effect the
encapsulated drugs with the nanoparticle material to disrupt the formation of biofilms [23]. Biofilm
is the assemblage of surface-associated microbial cells enclosed within extracellular polymeric
substance matrices that provide enhanced structural and functional properties to bacteria and their
cell walls [22,23,25,32]. Disruption of the biofilm could provide the edge required for antibiotics
to regain efficacy and effectively treat bacterial infections [25,27,31]. Nanotechnology could
provide the momentum to re-establish antibiotics as the gold standard of treatment against bacterial
infections.
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Chapter 2: Metal-Drug Complexes To Revive Antibiotics
Antibiotics were the epitome for revolutionizing modern medicine, yet became the
downfall of medicine with the rise of drug resistant bacteria [31]. Poor initiatives in industry to
synthesize and produce novel compounds led to the drying of the antibiotic pipeline [31]. Insights
have turned to synthesizing compounds of currently existing drugs and complexing these drugs
with a metal ion to create drug-metal complexes. Complexing of certain metals with drugs provide
fresh initiatives with new mechanisms of action to combat bacterial infections is of high
importance. Use of metal complexes along with nanotechnology could prove to be leading
advantages in solving the issue with single-drug and multiple-drug resistant bacteria.
SECTION 2.1. SIGNIFICANCE OF METAL COMPLEXES AS ANTIBACTERIAL AGENTS
Synthesis of existing drugs complexed with metal ions to produce a drug-metal complex
holds hopes of achieving three goals [33]. The first goal, would to create reversed mechanisms of
microbial resistance. The second, promote development of novel compounds with action
mechanisms unknown to bacteria. The third, to reduce toxicity of metal ions in form of complexes
with ease of metabolic degradation [33]. Drug-metal complexes present a favorable avenue in
solving the dilemma with synthesizing novel antibiotics for combating bacterial infections. Yet,
understanding the mechanisms of action and biological interactions is crucial for play as efficient
antibacterial agents.
Section 2.1.1. Common Metal Ions Within Biological Systems
Human biological systems are composed of 3% metal ions with various biological
processes and functions [34,35]. One of the better known metals within the human system is iron
(Fe), which is commonly used for cellular respiration and other biological processes and functions
[36]. Other metals commonly found include sodium (Na), potassium (K), calcium (Ca),
magnesium (Mg), copper (Cu), zinc (Zn), manganese (Mn), and cobalt (Co) (Figure 2.1) [37].
Each metal ion has various responsibilities in promoting cellular and subcellular functions. With
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the help of bioinformatics, scientists determined that ~ 50% of all enzymes depend on metal ions
for catalysis indicating the importance of metal ions with the promotion of life [37].

Figure 2.1: Abundance of elements found in the human biological system [37].
While the discovery of metal ions within biological systems is recent. Knowledge of metals
to combat and prevent bacterial infections has been understood for centuries. Ancient Egyptians
understood the use of Cu as a water sterilizer, along with Chinese and Arabic practices
incorporating gold as remedies against infections [35]. Silver (Ag), is one of the earliest recorded
metals to exhibit antibacterial activity [38]. Although these metals have been used for centuries to
prevent or treat bacterial infections, the threat of promoting gene transferring processes resulting
in metal ion resistance bacteria still exists [39].
Section 2.1.2. Drug-Metal Complexes Reviving Antibiotics
Research initiatives in recent years has increased to sought out possible solutions to the
rising issue of resistant bacteria. Interestingly, metal ions ligated with drugs to yield a metal-drug
complex show promise as an avenue to combat the threat of resistant bacteria [34,35,40,41].
Particularly metals with natural occurrence within biological systems, biometals, [37] due to the
inherent antibacterial activity. Other metals that do not normally occur in biological systems but
possessed antibacterial properties could also be investigated for activity against resistant bacteria.
Biometals complexed with various antibiotics had shown increased antibacterial activity
against resistant bacteria strains [34,41,42]. Those biometals included Cu, Zn, Ni, Fe, and Co ions
when complexed with various antibiotic ligands [33,34,42]. As these biometals were complexed,
7

enhancement of antibacterial activity for some combinations were observed. Foreign metals were
also investigated as potential candidates for effective metal-drug complex combinations [41,43].
Ag exhibited the highest antibacterial activity even at low concentrations and against the other
foreign metals continued to exhibit enhanced antibacterial activity even against biometals [34,43].
Because of Ag’s historical background as an antibacterial agent, favored economical standards,
and current applications with topical treatment was Ag determined as a viable candidate for further
exploration [34,38,40,44].
SECTION 2.2. SILVER COMPLEXES AS AN ANTIBACTERIAL AGENT
For over a millennia, Ag has been utilized as an antibacterial agent as early as 4000 BC
[38,40]. In 1884, silver nitrate (AgNO3) was introduced and utilized for the prevention of
ophthalmia neonatorum [38]. Mechanisms of action which Ag utilizes to combat bacteria occurred
via various pathways. These pathways included ionic interactions inhibiting DNA replication,
deactivating enzymatic activity, disruption to electron transport systems, poisoned respiratory
enzymes by reactive oxygen species (ROS) (Figure 2.2) [25,31,34]. More efficient dosage forms
were required, primarily to act as an antibacterial agent in treating infections and secondly to
prevent local toxicity to tissues and depletion of required electrolytes [38].

Figure 2.2: Antibacterial actions of silver (Ag) ions.
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The first Ag-complexed system was introduced in 1965, specifically silver sulfadiazine
(AgSD) to replace AgNO3 as the standard for treating P. aeruginosa infections [38,40,44]. AgSD
remained as the standard treatment for topical infections, but was associated with limitations. Low
stability due to Ag ions complexing with other available counter ions, precipitation of the AgSD
complex, and low solubility properties were some limitations [40]. Consequentially, overuse of
the complex led to the evolution of AgSD resistant bacteria [44]. With AgSD compromised, this
called for the investigation of novel silver complexes to combat resistant bacteria.
Research incentives focused on synthesizing various Ag-complexes with promise in
becoming gold standard treatment. Most intuitively, research has focused on the synthesis of Ag
complexed with ligands exhibiting synergistic effects to achieve primary goals of creating new
mechanisms of inhibition against resistant bacteria. Ag had been observed to strongly bind to
ligands with phosphorus and sulfur donors along with nitrogen and oxygen which could yield
stable complexes [38]. With strongly stable complexes, enhanced antibacterial activities could be
observed due to synergistic actions from both constituents. Although effective, this feat sacrificed
solubility for synergy and stability.
With the growing threat of resistant bacteria, it has become imperative that research
surrounding metal-drug complex synthesis not only aims to produce complexes but extends to
achieve all properties required for viable antibacterial agents. This would include improved
solubility, complex stability, synergistic activity, thermodynamic stability, and enhanced de/ligation kinetics. Acquiring all said requirements could produce a viable metal-drug complex with
enhanced antibacterial efficacy to eradicate the threat of resistant bacteria.
SECTION 2.3. SILVER-FUROSEMIDE COMPLEX AS NOVEL ANTIBACTERIAL
Recently, a novel Ag-complex with potential to act as an antibacterial agent was
synthesized. Particularly, the ligand of choice for complexation was not a former antibiotic agent.
Rather, the drug Furosemide (FSE) was chosen for complexing with Ag to form Ag-FSE [45]. In
normal practices, FSE is a sulfonylamide compound that belongs to a class of diuretics [46].
9

Although FSE would not normally be used for applications of bacterial treatment, it was observed
that FSE exhibited slight antibiofilm activity [45]. FSE’s antibiofilm activity is a vitality with
potential to cause a paradigm shift in the fight against resistant bacteria. Particularly, the
antibiofilm activity with FSE could be an advantageous property as FSE is not conventionally
utilized for antibacterial treatment. Thus, complexing FSE with a known antibacterial agent, Ag,
for synergistic effects could effectively treat bacterial infections of both resistant and non-resistant
in nature.
When complexing the Ag to FSE, it was observed that a hydrogen donation from the
carboxylic group of FSE occurred [45]. The conjugated Ag ion promoted a carbon shift to an
oxygen which resulted in a geometric spacing in the yielded product to be thermodynamically
stable resulting in high complex stability [45]. The increased complex stability arose due to
reinforced coordination of FSE to Ag via the carboxylate group [45] which allowed for
thermodynamically favorable bonding. Yet, this high stability also resulted with poor solubility
properties of the complex.
The Ag-FSE complex was observed to be insoluble in water and other organic solvents,
but remained highly soluble in dimethyl sulfoxide (DMSO) [45]. Ag-FSE’s insolubility ultimately
translated into poor permeability properties to effectively inhibit bacterial cell propagation [47].
The poor solubility properties of the Ag-FSE complex could also potentially cause hinderance on
the deligation kinetics of Ag to appropriately act on the bacterial cells [45,47]. Herein,
nanotechnology initiatives could prove advantageous with encapsulation of the Ag-FSE complex
into a drug delivery vehicle such as a nanoparticle. Encapsulation of Ag-FSE could result with
enhanced intrinsic complex properties leading to improved antibacterial efficacy with enhanced
solubility, controlled/sustained drug release, and appropriate nanoparticle characterization.

10

Chapter 3: Encapsulation of Silver-Furosemide Complex with Formulated
Chitosan Nanoparticles
With increasing challenges in antibiotic therapy, scientists are exploring novel
combinations of antibiotics, excipients and drug delivery carriers. These novel antibiotic drug
delivery systems are expected to be less susceptible to bacterial resistance. In addition to novel
drug delivery systems targeting bacterial infections, another approach is the complexation of
antimicrobials with silver (Ag), an antibacterial metal. These antibacterial metal complexes can be
further developed into nanoparticulate formulation for sustained and targeted release. Silver (Ag)
exhibits antibacterial activity via multiple mechanism of actions making it difficult for bacteria to
develop resistance [48]. Previously known complexes include silver sulfadiazine and clotrimazole
silver complex [38,49]. A complex of silver and furosemide (Ag-FSE) has been developed as an
antibacterial agent [45]. The poor solubility problem associated with Ag-FSE can be resolved
using nano drug delivery systems such as nanosuspensions, nano micelles, liposomes and
nanoparticles [50,51]. In recent years, chitosan has been widely used in the areas of bioengineering,
biopharmaceutical, and nanomedicine fields for the development of efficient drug delivery systems
[52]. CS is a synthetically produced biopolymer through a deacetylation process of a chitin, a
naturally occurring biopolymer in exoskeletons of insects, crustaceans, and fungi [53]. CS is
biocompatible, biodegradable and tunable for drug encapsulation and controlled drug release.
Considering the advantages with CS, we hypothesize that chitosan nanoparticles loaded with AgFSE can improve solubility and antibacterial activity. The formulated of Ag-FSE-CSNPs were
evaluated for size, zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (EE%),
antibacterial activity and stability.
SECTION 3.1. MATERIALS
Furosemide was purchased from Acros Organics (New Jersey, USA). Chitosan, 85%
deacetylated powder was procured from Alfa Aesar (Ward Hill, MA). Silver nitrate (AgNO 3),
potassium hydroxide (KOH), sodium triphosphate (TPP), dimethyl sulfoxide (DMSO), buffer
11

salts, acetic acid and methanol (ACS grade) were obtained from Fisher Scientific (Fair Lawn, NJ,
USA). Deionized water used in experiments was obtained from Milli-Q® IQ 7000 Ultrapure Water
System (Millipore, Bedford, MA, USA). Dialysis tubing with MWCO of 14,400 was procured
from Sigma-Aldrich (St. Louis, MO, USA). Mueller-Hinton broth (CM0405) was obtained from
Oxoid Microbiology Products (USA), bacterial strains were purchased from the American Type
Culture Collection (ATCC), and sterile microtiter plates were procured from Fisher Scientific (Fair
Lawn, NJ, USA).
SECTION 3.2. METHODS
Section 3.2.1. Synthesis of Ag-FSE complex
Synthesis of the Ag-FSE complex was performed as reported by Lustri et al. 2017 with
minor modifications to the procedure (Figure 3.1) [45]. Briefly, an aqueous solution (2 ml) of
AgNO3 (2.13 mmol, 0.362 g) was added dropwise into a methanolic solution (20 ml) of furosemide
(0.704 g, 2.13 mmol) and KOH (0.119 g, 2.13 mmol) with stirring. This reaction mixture was then
subjected to continuous stirring at room temperature for 2h and a final product of white precipitate
was collected by filtration. The white precipitate of Ag-FSE Complex was then washed with cold
water three times and dried in a desiccator overnight under negative pressure for 24 h.

O

Cl O
O
S
NH2
NH
HO

KOH, MeOH
H2O, AgNO3
rt, 2h

O

O

Cl O
O
S
NH2
NH
O

O
-

Ag

Figure 3.1. Synthesis of Ag-FSE complex.
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Section 3.2.2. Preparation of CSNPs
CSNPs were formulated by ionic gelation technique as described by Kalhapure et al. 2017
with slight modifications, for both blank and Ag-FSE loaded nanoparticles [54]. For the
preparation of blank CSNPs, CS solution (10 ml) (1% w/v in 1% acetic acid) was kept under
stirring at 1000 rpm for 10 minutes followed by dropwise addition of 0.1% w/v TPP solution (20
ml) under continuous stirring. The resultant solution was kept under stirring for 5 minutes after the
addition of all TPP solution. The pH of the final solution was adjusted to 5.5 with 0.5 M NaOH.
Following this, the formulation was sonicated at 30% amplitude using probe sonicator (Fisher
scientificTM Model 505 Sonic Dismembrator) in an ice bath. Thereafter, the formulation was
stirred at 1000 rpm for 20 minutes in the dark. Ag-FSE loaded CSNPs were prepared using the
same method as blank CSNPs. A weighed amount of the Ag-FSE complex was added into the TPP
solution (20 ml) and then subjected to probe sonication at 30% amplitude. During sonication the
solution was kept in an ice bath to maintain room temperature. The homogenous Ag-FSE-TPP
solution was then added dropwise into CS solution (10 ml) and processed further as the blank
CSNPs to obtain Ag-FSE loaded CSNPs.
Section 3.2.3. Determination of size, PDI, and ZP
The size, PDI, and ZP analysis of the CSNPs was performed using dynamic light scattering
(DLS) technique. CSNPs (100 µl) were dispersed in deionized water (10 ml) and measurements
were performed with a Zetasizer Nano ZS90 (Malvern Zetasizer Nano ZS90, Malvern Instrument
Ltd., UK) at 25℃ and 90 o scattering angle.
Section 3.2.4. Morphology Studies
Single drop of dilute dispersion of Ag-FSE CSNPs were placed on gold grids, with excess
of liquid dispersion on gold grid been wicked using a piece of filter paper. The grid was kept for
drying in a sterile fume hood for two days. The sample grid was then transferred into the STEM
(Hitachi HD-2300A) where images were recorded in transmission electron microscopy (TEM)
mode at 200kV.
13

Section 3.2.5. Drug encapsulation efficiency (EE%)
Drug loaded Ag-FSE CSNP encapsulation efficiency was determined using a modified
ultrafiltration technique [55]. Ag-FSE loaded CSNPs (500 µl) were pipetted into Ultracel®
centrifugal filter units with a MWCO of 10 kDa. These samples were then centrifuged at 10,000
rpm (accuSpin Micro 17R, Fisher Scientific, USA) for 30 minutes at 20 °C allowing for the
separation of unentrapped drug from encapsulated drug. After centrifugation, filtrate was collected
and 300 µl was diluted to 3 ml with milli-Q water and analyzed using UV-spectrophotometer (UVvis) (Shimadzu UV-1800, Japan) at max = 277 nm. The regression equation used for calculations
was y = 0.0486x + 0.0135 with R2 = 0.9995. EE% of the CSNPs was determined using Equation
3.1.

EE% = (Total drug – Free drug)/ (Total drug) × 100
Equation 3.1. EE% of Ag-FSE complex with CSNPs.
Section 3.2.6. X-ray diffraction (XRD)
XRD analysis of the Ag-FSE CSNPs was performed using PANanlytical’s X-ray
diffractometer (PANanlytical’s X’pert Pro Tokyo, Japan) equipped with X’Celerator high speed
detector. XRD studies were performed for CS, TPP, Ag-FSE and Ag-FSE CSNPs. Powdered
samples were placed on an aluminum sample holder and uniformly packed using glass slide.
Radiation source was CuKα operated at 45 kV and 40 mA. All the measurements were recorded
with continuous scanning mode over a 2θ range of 5o to 70o.
Section 3.2.7. Differential scanning calorimetry (DSC)
DSC analysis for Ag-FSE CSNPs and CS was performed using DSC Q20 instrument with
TA universal analysis software to obtain scans. Samples (5 -10 mg) were placed in aluminum pans
and sealed. DSC analysis was performed at a heating rate of 10 oC/min over a range of 40 oC to
300 oC with a nitrogen flow of 20 ml/min.
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Section 3.2.8. In vitro drug release studies
Drug release behavior from the CSNPs and free drug (Ag-FSE) in phosphate buffer saline
(PBS) (pH 7.4, 6.5 and 5.5) was evaluated using the dialysis bag method (MW 8000 – 14,400 Da)
[56,57]. Briefly, 3 ml of Blank CSNPs, Ag-FSE and Ag-FSE CSNPs in PBS were transferred into
separate dialysis bags. These dialysis bags were placed in conical tubes (50 ml capacity) containing
30 ml of PBS as the release medium (pH 7.4, 6.5 and 5.5) maintained at 37 ± 0.5 o C in a shaking
water bath (100 rpm). At a pre-determined time-intervals, 3 ml of the samples were collected from
the conical tubes and replaced with 3 ml of fresh PBS to maintain sink conditions. Pre-determined
time intervals were 0.5, 1, 2, 3, 4, 5, 6, 7, 8, and 24h. The amount of drug released from the
formulations at different timepoints was quantified using a UV-visible spectrophotometer
(Shimadzu UV 1800, Japan) at λmax = 277 nm. All the experiments were performed in triplicate.
Section 3.2.9. In vitro antibacterial activity
Ag-FSE loaded CSNPs and free Ag-FSE were evaluated for antibacterial activity against
E. coli (ATCC25922) and S. aureus (ATCC25923) using a broth microdilution method. Colonies
of each bacteria were grown overnight in Muller-Hinton broth (MHB) in an incubator at 37 °C.
Single bacterial culture colonies of each bacteria were suspended in MHB and further diluted with
MHB until a cell density of 0.5 Mcfarland for each bacterium was attained. Diluted bacterial
suspensions (100µL) were transferred into 96-well plates. Upon seeding with designated bacteria,
serial dilutions of 100 µL of Ag-FSE CSNPs, blank CSNPs, free Ag-FSE in 10% w/v DMSO,
MHB, and plain 10% DMSO were performed. Plates were incubated overnight at 37 °C and
minimum inhibitory concentration (MIC) was assessed as the concentration at which no bacterial
growth was observed. All experiments were completed in triplicate.
Section 3.2.10. Stability studies
Three batches of Ag-FSE CSNPs were prepared under optimum conditions and their size,
PDI and ZP were analyzed. Thereafter, the samples were stored at 25 °C and 4 °C conditions.
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Stability was assessed using DLS analysis for four months (120 days). The parameters monitored
to assess the stability were physical appearance, size, PDI and ZP.
Section 3.2.11. Statistical analysis
Statistical analysis was performed using t-test followed by Bonferroni's multiple
comparison test using GraphPad Prism® (Graph Pad Software Inc., Version 5.0, San Diego, CA).
A p-value < 0.05 was considered statistically significant.
SECTION 3.3. RESULTS & DISCUSSION
Section 3.3.1. CSNP Characterization
Section 3.3.1.1. Effect of sonication time on blank and Ag-FSE CSNPs
Blank CSNPs and Ag-FSE CSNPs were formulated by ionic gelation technique. Effect of
sonication time on the size, PDI and ZP of CSNPs was studied. Table 3.1 and Figure 3.2
summarizes the effect of sonication time (3, 5, 10 and 20 minutes at 30% amplitude) on size, PDI
and ZP on blank CSNPs. Size, PDI and ZP of CSNPs ranged from 204.8 ± 4.428 to 472.1 ± 42.81,
0.195 ± 0.023 to 0.517 ± 0.107, and 36.0 ± 2.54 to 44.1 ± 2.21 respectively. It was observed that
with increasing sonication time there was a significant decrease in particle size from 3 to 10
minutes, however, at 10 minutes and 20 minutes there was no significant difference (p > 0.05) in
particle size. Thus, 10 minutes of sonication was considered as optimum sonication time for
preparing CSNPs with < 300 nm size, low PDI and high ZP. Low PDI and high ZP of CSNPs
suggests that the system was monodispersed and electrostatically stable. Similar results were
observed by Tang et.al where increase in sonication time caused cleaving free unpolymerized
chitosan, reducing particle size and enhancing monodispersity of the system [58].
Table 3.1: Effects of sonication time on size, PDI, and ZP of CSNPs.
Time (minutes)
3

Size (nm)
344.6 ± 98.96

PDI
0.517 ± 0.107

ZP (mV)
44.1 ± 2.21

5

472.1 ± 42.81

0.507 ± 0.139

42.9 ± 3.86

10

261.3 ± 12.23

0.195 ± 0.023

42.8 ± 1.31

16

20

204.8 ± 4.428

0.205 ± 0.019

36.0 ± 2.54

Figure 3.2: Effect of sonication time on size of blank CSNP; *significant difference with CSNP
size at 5- and 10-minute sonication (p < 0.05); ns, non-significant.
After optimizing the sonication time for blank CSNPs, the effect of sonication time on the
size of Ag-FSE CSNPs was studied. Initially, 5 mg Ag-FSE was loaded into the CSNPs and
analyzed for differences in size, PDI, and ZP with respect to 5 and 10-minute sonication times.
Effect of sonication time on the size, PDI and ZP of Ag-FSE CSNP is provided in Table 3.2 and
Figure 3.3. Results confirmed that there was a significant difference with respect to size between
5 minutes and 10 minutes sonication (p < 0.05). Therefore, 10 minutes was considered as the
optimum sonication time both blank and Ag-FSE CSNPs.
Table 3.2: Effects of sonication time on CSNPs loaded with 5 mg of Ag-FSE.
Time (minutes)

Size (nm)

PDI

ZP (mV)

5

481.4 ± 28.95

0.520 ± 0.100

42.2 ± 2.44

10

290.3 ± 162.6

0.395 ± 0.222

35.5 ± 1.52
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Figure 3.3: Effect of sonication time on size of Ag-FSE CSNPs (5mg). *significant difference
with CSNP sizes (p < 0.05).
Section 3.3.1.2. Effect of drug loading on size, PDI, and ZP of Ag-FSE CSNPs
After the preliminary studies, 10 minutes was considered the optimum sonication time for
the formulation of Ag-FSE CSNPs. Effect of increased drug loading (10 mg) on the size, PDI and
ZP of Ag-FSE was studied and summarized in Table 3.3 and Figure 3.4. Interestingly, it was found
that increase in Ag-FSE loading from 5 mg to 10 mg resulted in CSNPs with significantly smaller
particle size (p < 0.05). Size, PDI and ZP of 10 mg loaded Ag-FSE CSNPs was 216.6 ± 26.80 nm
0.194 ± 0.021 and 25.8 ± 3.05 mV respectively. The low PDI values and high ZP indicate that
under 10-minute sonication with 10 mg loaded into the CSNPs continued to exhibit monodispersity
and electrostatic stability. With higher dosage loading the size of the CSNPs will remain optimal
with < 300 nm sizes as no significant differences (p > 0.05) was observed with size being affected
from higher dosage.
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Table 3.3: Effects of drug loading on size, PDI, and ZP of CSNPs.
Ag-FSE loading Size (nm)
(mg)
5
290.3 ± 162.6

PDI

ZP (mV)

0.395 ± 0.222

35.5 ± 1.52

10

0.194 ± 0.021

25.8 ± 3.05

216.6 ± 26.80

Figure 3.4: Effect of drug loading on size of CSNPs. *significant difference between 5 mg and
10 mg loading (p < 0.05).
Section 3.3.2. Morphology
TEM images of the Ag-FSE CSNPs indicated that the nanoparticles were globular in shape
(Figure 3.5). Analysis of the Ag-FSE CSNP morphology indicated that a decrease in particle size
occurred when compared to DLS results due to dehydration of the particles when undergoing
drying on the gold grids for preparation of TEM analysis [59].
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Figure 3.5: TEM images of Ag-FSE loaded CSNPs, nanoparticles appeared globular in
shape.
Section 3.3.3. Drug encapsulation efficiency (EE%)
Ag-FSE CSNPs showed high encapsulation with EE% of 66.72 ± 4.14 %. The high EE%
for Ag-FSE could be attributed to the electrostatic nature of the two constituents. CS being cationic
while Ag-FSE complex holds an anionic nature, allowing the polymerization of CS and
formulation of the nanoparticles with loaded drug [60].
Section 3.3.4. XRD
As silver complexes inherently reported to have poor aqueous solubility [38], it is crucial
to study the crystalline nature of the formulation. Crystalline nature of the drug can affect the
solubility, stability and bioavailability. XRD was performed for Ag-FSE, CS, and Ag-FSE CSNPs
to confirm the crystalline nature. Results showed that Ag-FSE exhibited crystalline nature with
characteristic peaks at 6.18o, 10.28o, 18.48o, 25.92o, and 32.8o. However, when Ag-FSE was
encapsulated into CSNPs, it was observed that Ag-FSE had undergone phase transition from
crystalline to amorphous state (Figure 3.6). The transition can be confirmed by absence of the
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characteristic peaks of Ag-FSE in the XRD of Ag-FSE CSNP (Figure 3.6c). Similar findings were
observed with other CSNP formulations [61].

Figure 3.6: XRD results for (a) plain Ag-FSE, (b) plain CS and (c) Ag-FSE CSNPs.
Section 3.3.5. DSC
DSC evaluates the melting and crystalline behavior of drugs. Phase transition of Ag-FSE
from crystalline to amorphous form was further confirmed by DSC. Results of Ag-FSE, CS and
Ag-FSE CSNPs are provided in Figure 3.7. Thermograms showed that Ag-FSE had a sharp
exothermic peak at 211.69 °C. However, the characteristic exothermic peak of Ag-FSE was absent
in DSC of Ag-FSE CSNPs confirming the encapsulation of Ag-FSE into CSNPs.
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Figure 3.7: DSC results of (a) Ag-FSE, (b) CS and (c) Ag-FSE CSNPs.
Section 3.3.6. In vitro drug release studies
Ag-FSE encapsulated CSNPs showed sustained release with cumulative release of ~75%
for over a period of 24 hours. In vitro drug release profiles of Ag-FSE CSNPs and free Ag-FSE
are provided in Figure 3.8. As bacterial infections are associated with varying pH at the infection
site, release profiles at physiological pH (7.4) and acidic pH (6.5 and 5.5) were also studied (Figure
3.9). Ag-FSE CSNPs showed sustained and controlled release over a period of 24 hours at all pH’s.
At pH 5.5 and 6.5, the CSNPs had an initial burst like release during the first 4 hours with a
cumulative release ranging from 41.78 % – 70.57 %. This initial burst could be due to
unencapsulated Ag-FSE molecules that remained along the surface of the CSNPs [62]. It was
observed that at pH 5.5 and 6.5 conditions ~ 42 – 44% of Ag-FSE was released within 0.5 hours
whereas, at pH 7.4 only ~ 29% release was observed in first 0.5 hours. Similar release profile was
observed with CS under acidic conditions [56]. Whereas with the free Ag-FSE complex, the
release was greater at all time points compared to nanoparticles (Figure 3.8). A significant
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difference between encapsulated Ag-FSE with CSNPs versus free Ag-FSE drug release was
observed (p < 0.0001).

Figure 3.8: In vitro release profile of Ag-FSE in PBS and Ag-FSE CSNPs. Data is expressed in
mean ± SD (n = 3).
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Figure 3.9: In vitro release profile of Ag-FSE CSNPs at pH 7.4, 5.5 and 6.5. Data is expressed in
mean ± SD (n = 3).
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Section 3.3.7. In vitro antibacterial activity
In vitro antibacterial activity was assessed by broth microdilution method. Results showed
that Ag-FSE CSNPs exhibited significantly greater inhibitory activity against E. Coli and S. aureus
compared to Ag-FSE. Against E. coli, MIC of Ag-FSE was 166.5 µg/ml whereas value for plain
Ag-FSE was 500 µg/ml. There was a 6-fold enhancement in activity against S. aureus (Table 3.4).
The MIC values suggested that the Ag-FSE loaded CSNP formulation had notably greater
antibacterial activity compared to unencapsulated drug. These synergistic characteristics may be
due to CS being a bioactive polymer with antibiofilm and antimicrobial properties [63]. Results
confirmed that encapsulation of Ag-FSE in to CSNPs enhanced the antibacterial efficiency of AgFSE.
Table 3.4: Minimum Inhibition Concentration (MIC) for Blank CSNP, Ag-FSE CSNP, Ag-FSE
in 10% DMSO and 10% DMSO against E. coli and S. aureus (n = 3).
Formulation

MIC (µg/ml)

Blank CSNPs
Ag-FSE CSNPs

E. coli
NA
166.5

S. aureus
NA
41.63

Ag-FSE in 10% DMSO

500

250

10% DMSO

NA

NA

Section 3.3.8. Stability Studies
Stability studies were performed on both 5 mg and 10 mg Ag-FSE loaded CSNPs over 120
days. Size, PDI and ZP were investigated to confirm the physical stability of CSNPs. Formulations
were stored at 4 °C and 25 °C, and analyzed over the course of time (day 0, 30, 60 and 120).
Stability study results for 5 mg and 10 mg Ag-FSE loaded CSNPs are provided in Table 3.5 and
Table 3.6 respectively. Results showed that there was a steady decrease in the size of the 5 mg AgFSE loaded CSNPs from days 30 to 60. The decreased size may be due to the cationic and anionic
interactions of CS and Ag causing the particle size to decrease [64]. Also, 10 mg Ag-FSE loaded
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CSNPs stored at 25 °C showed slight increase in size for 4 °C. Day 120 analysis indicated an
increase in particle size for both 5 mg and 10 mg Ag-FSE loaded CSNPs. The increased size may
be due to particle aggregation or swelling caused by changes in environmental conditions
(temperature, pH, ionic strength) [65]. The overall difference in size, PDI and ZP of all the samples
at different time points was not significant (p > 0.05). Therefore, both the formulations can be
considered stable at 25 °C and 4 °C for 120 days.
Table 3.5: Effect of storage on particle size, PDI and ZP of 5 mg loaded CSNPs for 30, 60 and
120 days at 4 °C and 25 °C.
Storage Time
Size (nm)

Day 0
Day 30
Day 60
Day 120

4 °C
290.3 ± 162.6
239.8 ± 9.877
229.7 ± 3.167
296.8 ± 2.769

25 oC
290.3 ± 162.6
241.5 ± 5.568
232.0 ± 11.19
331.8 ± 16.11

PDI
4 °C
0.395 ± 0.222
0.224 ± 0.023
0.217 ± 0.008
0.236 ± 0.014

ZP (mV)
25 oC
0.395 ± 0.222
0.191 ± 0.021
0.242 ± 0.018
0.288 ± 0.038

4 °C
25 oC
35.5 ± 1.52 35.5 ± 1.52
33.7 ± 1.70 35.6 ± 1.08
39.0 ± 2.09 35.5 ± 8.90
29.8 ± 2.03 30.7 ± 0.66

Table 3.6: Effect of storage on particle size, PDI and ZP of 10 mg loaded CSNPs for 30, 60 and
120 days at 4 °C and 25 °C.
Storage Time
Size (nm)

Day 0
Day 30
Day 60
Day 120

4 °C
216.6 ± 26.80
224.6 ± 13.78
217.4 ± 5.276
324.8 ± 50.74

25 °C
216.6 ± 26.80
176.5 ± 10.49
207.3 ± 9.907
321.7 ± 33.53

PDI
4 °C
0.194 ± 0.021
0.217 ± 0.025
0.232 ± 0.017
0.587 ± 0.162

25

25 °C
0.194 ± 0.021
0.272 ± 0.030
0.248 ± 0.018
0.407 ± 0.021

ZP (mV)
4 °C
25 °C
25.8 ± 3.05 25.8 ± 3.05
30.5 ± 11.1 30.3 ± 5.45
37.3 ± 3.79 36.2 ± 6.61
39.7 ± 1.92 37.3 ± 2.40

Conclusions
In the present study we successfully encapsulated a novel antibacterial complex, Ag-FSE,
into CSNPs for enhancement in its antibacterial efficacy. The size of formulated Ag-FSE CSNPs
was < 300 nm with high %EE of ~ 66 %. Ag-FSE CSNPs were globular in shape with smooth
surfaces. XRD and DSC confirmed the transition of Ag-FSE from crystalline to amorphous form.
Ag-FSE CSNPs showed significant antibacterial activity against E. Coli (Gram negative) and S.
aureus (Gram positive). Stability studies indicated that the Ag-FSE CSNPs at 4 °C and 25 °C
conditions remained stable over 120 days. Further exploration of developed CSNPs with in depth
in vivo studies could lead to its further transition to clinical trials.
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